Ascendis Pharma AS (ASND) Superinvestor holders
14 of the superinvestors we track hold Ascendis Pharma AS (ASND) in their latest 13F filings, $1.0B in total.
Summary
The largest holder is Artisan Partners, with $703M, 1.1% of the portfolio.
In their latest quarter: 14 opened a new position.
Who holds it
Each investor's latest 13F filing, largest stake first. What a 13F shows.
| Investor | Last change | Shares | Value | % of portfolio | Filed for |
|---|---|---|---|---|---|
| Artisan Partners | New position | 2,634,024 | $703M | 1.1% | Q2 2026 |
| Two Sigma Two Sigma Investments |
New position | 305,803 | $82M | 0.1% | Q2 2026 |
| James Robillard Spyglass Capital Management |
New position | 215,398 | $57M | 3.1% | Q2 2026 |
| Alger Fred Alger Management |
New position | 171,447 | $46M | 0.2% | Q2 2026 |
| Arrowstreet Capital | New position | 125,772 | $34M | 0.0% | Q2 2026 |
| Jim Simons Renaissance Technologies |
New position | 119,699 | $32M | 0.0% | Q2 2026 |
| Aziz Hamzaogullari Loomis Sayles & Co |
New position | 78,941 | $21M | 0.0% | Q2 2026 |
| David Shaw D. E. Shaw & Co. |
New position | 30,883 | $8M | 0.0% | Q2 2026 |
| David Vogel Voloridge Investment Management |
New position | 29,303 | $8M | 0.0% | Q2 2026 |
| Paul Marshall Marshall Wace |
New position | 22,503 | $6M | 0.0% | Q2 2026 |
| Paul Tudor Jones Tudor Investment Corp |
New position | 16,625 | $4M | 0.0% | Q2 2026 |
| Alan Howard Brevan Howard |
New position | 7,930 | $2M | 0.0% | Q2 2026 |
| Ensign Peak Ensign Peak Advisors |
New position | 7,116 | $2M | 0.0% | Q2 2026 |
| Ron Baron Baron Capital (BAMCO) |
New position | 1,500 | $400,080 | 0.0% | Q2 2026 |
Questions about Ascendis Pharma AS
Which superinvestors own Ascendis Pharma AS?
14 of the superinvestors we track hold Ascendis Pharma AS (ASND) in their latest 13F filings, $1.0B in total. Artisan Partners, Two Sigma, James Robillard, Alger, Arrowstreet Capital, Jim Simons.
Who is the largest superinvestor holder of ASND?
The largest holder is Artisan Partners, with $703M, 1.1% of the portfolio.
From Ascendis Pharma AS's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.